Tuesday, February 23, 2021
Study on two corona vaccines
Hardly any hospital stays necessary after vaccination
Even the first vaccination with the Astrazeneca vaccine can reduce the risk of hospitalization for Covid-19 by up to 94 percent. This comes from an analysis by Scottish universities and the health authority. Biontech’s vaccine reduces the risk with the first dose by 85 percent.
According to a preprint study, the corona vaccination campaign in Scotland has significantly reduced the burden on hospitals. Four weeks after the first dose of the Biontech / Pfizer corona vaccine was vaccinated, the recipient’s risk of hospitalization for Covid-19 drops by up to 85 percent, according to a study by the University of Edinburgh. With the Astrazeneca vaccine, the risk is reduced by 94 percent.
“These results are very encouraging and give us good reason to look to the future with optimism,” said study leader Aziz Sheikh. It is now proven that the vaccination against the coronavirus offers “protection against Covid-19-related hospital stays”. Sheikh campaigned for a worldwide acceleration of the corona vaccination campaign. This could help “overcome this terrible disease”.
The researchers analyzed a huge data set to establish links between pandemic development and vaccination progress. For the study, which has not yet been published in a specialist magazine, they used data from 5.4 million people, almost the entire Scottish population. Between December 8 and February 15, around 1.14 million doses of corona vaccine were given to around 21 percent of the population in Scotland. 650,000 people in Scotland received the vaccine from Biontech / Pfizer and 490,000 the preparation from Astrazeneca.
Results applicable to other countries
For people over 80 years of age, the risk of having to go to hospital for Covid-19 decreased by 81 percent in the fourth week after the first vaccination, according to the study. According to the study authors, the results of the study can also be applied to other countries that use the vaccines from Astrazeneca and Biontech / Pfizer.
The President of the British Society for Immunology, Arne Akbar, called the results of the study “extremely promising”. There are differences in the effectiveness of the vaccines across the various age groups. “The reduction in hospital stays among the older age groups is still remarkably high,” said Akbar.
